{"nctId":"NCT01403116","briefTitle":"Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","startDateStruct":{"date":"2011-07"},"conditions":["Male Hypogonadism"],"count":325,"armGroups":[{"label":"Oral testosterone undecanoate (TU)","type":"EXPERIMENTAL","interventionNames":["Drug: Oral testosterone undecanoate"]},{"label":"topical testosterone gel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: topical testosterone gel"]}],"interventions":[{"name":"Oral testosterone undecanoate","otherNames":["Oral TU"]},{"name":"topical testosterone gel","otherNames":["T-gel"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Serum testosterone of less than or equal to 300 ng/dL on two occasions within one week (may wash out from previous oral, topical or buccal testosterone therapy)\n\nExclusion Criteria:\n\n* Significant intercurrent disease of any type, in particular liver, kidney, uncontrolled or poorly controlled heart disease, or psychiatric illness\n* Recent history of stroke, not including transient ischemic attack\n* Untreated, sever obstructive sleep apnea.\n* Hematocrit \\<35% or \\>48\n* Serum transaminases \\>2 times upper limit of normal, serum bilirubin \\> 2.0 mg/dL and serum creatinine \\> 2.0 mgk/dL\n* BMI \\> or equal to 36\n* Stable doses of lipid-lowering medication for less than 3 months\n* Stable doses of oral medication for diabetes for less than 2 months\n* Abnormal prostate DRE \\[palpable nodule(s)\\], elevated PSA (\\>4 ng/mL), IPSS score \\> or equal to 19 points.\n* History of breast cancer\n* Use of dietary supplement saw palmetto or phytoestrogens and use of any dietary supplements that may increase serum testosterone within previous 4 weeks\n* Known malabsorption syndrome and/or current treatment with oral lipase inhibitors\n* History of abuse of alcohol or any drug substance within the previous 2 years\n* Current use of antiandrogens, estrogens, oral CYP3A4 inducers or inhibitors, or long-acting opioid analgesics\n* Receipt of any drug as part of a research study within 30 days of initial dose administration in this study.\n* Blood donation within the 12 week period before the initial study dose.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Treated Patients With Average Serum Testosterone (T) Concentrations (Cavg) Between 300 and 1000 ng/dL","description":"The percentages of treated subjects that had 24-hour serum testosterone (T) average concentrations (Cavg) between 300 and 1000 ng/dL","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":null},{"groupId":"OG001","value":"79.2","spread":null}]}]}]},{"type":"SECONDARY","title":"% of Oral TU Subjects With 24-hour Maximum Serum T Concentrations (Cmax) Greater Than 1500 ng/dL on Day 90","description":"Percentage of Oral TU treated patients who reached study day 90 and had a maximum serum T concentrations (Cmax) values greater than 1500 ng/dL(objective to meet \\<15%).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":161},"commonTop":["Polycythaemia","Nasopharyngitis","Hypertension","Upper respiratory tract infection","Prostatomegaly"]}}}